2020-08-12T10:33:25-05:00 2019-09-30 ERNST & YOUNG US LLP 200 CLARENDON STREET BOSTON MA 021165072 990 2018-10-01 042263040 Dana-Farber Cancer Institute Inc % MELISSA CHAMMAS DANA 6176323000 450 Brookline Avenue BP418 Boston MA 02215 MICHAEL RENEY CFO 6176323000 2020-08-04 true BARBARA E HUNT P00916443 6172662000 2020-07-30 76.19.246.55 04750420202255000008 2020-08-12 P 120CEB144A09B0F247B212AAF84468814E75FA3B 79DE44365921E24D8255237D08E513902394227B 2018 2020-09-23 17:36:50Z Laurie H Glimcher MD 450 BROOKLINE AVE Boston MA 02215 1990678088 false X www.dana-farber.org X 1951 MA THE MISSION OF DFCI IS TO PROVIDE EXPERT, COMPASSIONATE CARE TO CHILDR COMPASSIONATE CARE TO CHILDREN AND ADULTS WITH CANCER & ADVANCE THE TREATMENT, CURE, AND PREVENTION OF CANCER & RELATED DISEASES. 58 57 6457 600 88157 0 561378936 604363420 1151473141 1270430919 25907335 2681916 16378704 108033389 1755138116 1985509644 8963365 5367834 0 0 537676542 608704290 3832226 4127668 39814387 1130830256 1265093471 1681302389 1883293263 73835727 102216381 2890706000 3127097000 1135834597 1182642732 1754871403 1944454268 X THE MISSION OF DANA-FARBER CANCER INSTITUTE IS TO OPERATE, CONDUCT AND SUPPORT AN INSTITUTE FOR RESEARCH INTO THE CAUSES, TREATMENT AND PREVENTION OF CANCER AND OTHER DISEASES IN CHILDREN AND ADULTS AND TO PROVIDE FOR THE CARE, TREATMENT AND NURSING OF PERSONS HAVING SUCH DISEASES, AND IN FURTHERANCE OF THE FOREGOING, TO CONSTRUCT, OPERATE AND MAINTAIN A HOSPITAL OR HOSPITALS, A CANCER CENTER AND OTHER FACILITIES IN BOSTON, MASSACHUSETTS, ANYWHERE IN THE UNITED STATES OF AMERICA OR ELSEWHERE IN THE WORLD TO PROVIDE FOR PERSONS WITH CANCER AND OTHER DISEASES REGARDLESS OF AGE; TO PROMOTE HEALTH CARE IN COMMUNITIES AROUND THE WORLD BY EDUCATING AND SUPPORTING OTHER PROVIDERS IN EFFECTIVE CANCER CARE AND RESEARCH; AND TO CARRY ON ALL ACTIVITIES RELATED OR INCIDENT THERETO INCLUDING, BUT WITHOUT LIMITATION HERETO, RESEARCH, STUDY, TEACHING, CLINICAL INVESTIGATION, CARE OF PATIENTS AND TRAINING OF MEDICAL STUDENTS, SCIENTISTS, NURSES, RESEARCH ASSISTANTS AND PARAMEDICAL PERSONNEL. false false 1062386759 1270430919 CLINICAL CARE AS ONE OF THE LEADING CANCER CENTERS IN THE WORLD, DANA-FARBER CANCER INSTITUTE (DFCI) PROVIDES COMPASSIONATE, COMPREHENSIVE, AND PERSONALIZED CARE TO ADULTS AND CHILDREN WITH CANCER, BLOOD DISORDERS, AND RELATED DISEASES. IN FISCAL YEAR 2019, OUR EXPERT CLINICIANS AND CAREGIVERS AT OUR SPECIALIZED TREATMENT CENTERS WORKED TOGETHER TO DELIVER THE LATEST THERAPIES TO OUR PATIENTS THROUGH 1,568 INPATIENT ADMISSIONS, 359,519 OUTPATIENT MD VISITS, AND 187,664 INFUSION TREATMENTS. SINCE ITS FOUNDING IN 1947 BY SIDNEY FARBER, MD, DANA-FARBER HAS FOLLOWED HIS VISION FOR A CANCER CENTER THAT IS JUST AS DEDICATED TO DISCOVERIES IN CANCER RESEARCH AS IT IS TO DELIVERING EXPERT, COMPASSIONATE CARE. DANA-FARBER IS A FOUNDING MEMBER OF DANA-FARBER/HARVARD CANCER CENTER AND ONE OF 51 NCI-DESIGNATED COMPREHENSIVE CANCER CENTERS IN THE U.S. DANA-FARBER IS THE ONLY HOSPITAL RANKED IN THE TOP FOUR NATIONALLY BY U.S NEWS AND WORLD REPORT IN BOTH ADULT AND PEDIATRIC CANCER CARE. IN 2019, WE OFFERED MORE THAN 1,100 CLINICAL TRIALS. 592175647 RESEARCH SCIENTIFIC WORK AT DANA-FARBER IS BASED ON THE PREMISE THAT BASIC AND CLINICAL INVESTIGATION ARE COMPLEMENTARY AND REINFORCING ACTIVITIES. TO ENCOURAGE THIS CROSS-POLLINATION OF IDEAS, THE INSTITUTE HAS DEVELOPED AN ORGANIZATIONAL FRAMEWORK THAT FOSTERS COLLABORATIONS AMONG INVESTIGATORS FROM DIFFERENT DISCIPLINES. THE RESULT IS AN INTENSE SCIENTIFIC IMPACT ON A GROUP OF DISEASES THAT CONTINUE TO REPRESENT ONE OF HUMANITYS GREATEST HEALTH CHALLENGES. SOME RECENT ADVANCES INCLUDE: OVERCOMING RESISTANCE TO IMMUNOTHERAPY: A TEAM OF RESEARCHERS AT DANA-FARBER AND THE BROAD INSTITUTE OF MIT AND HARVARD IDENTIFIED A PATTERN OF GENE ACTIVITY IN HUMAN MELANOMA CELLS THAT ENABLES THEM TO RESIST IMMUNOTHERAPY. THE RESEARCHERS DEMONSTRATED THAT A COMBINATION OF THERAPIES COULD OVERCOME THIS RESISTANCE. PARP INHIBITORS OPEN TWO-FRONT ATTACK ON CANCER: DANA-FARBER RESEARCHERS SHOWED THAT PARP INHIBITORS DRUGS DESIGNED TO KILL CANCER CELLS BY HINDERING THE REPAIR OF DNA CAN ALSO SPARK AN IMMUNE SYSTEM ATTACK ON SUCH CELLS. PREVENTIVE SURGERY AND QUALITY OF LIFE: AS MORE YOUNG WOMEN WITH BREAST CANCER OPT TO HAVE MASTECTOMIES, MANY EXPERIENCE A PERSISTENT DECLINE IN THEIR SEXUAL AND PSYCHOSOCIAL WELL-BEING, DANA-FARBER INVESTIGATORS REPORTED. THE FINDINGS UNDERSCORED THE IMPORTANCE OF COUNSELING PATIENTS ABOUT THE POTENTIAL LONG-TERM PHYSICAL AND EMOTIONAL CONSEQUENCES OF THE PROCEDURE. BLOOD TEST FOR CANCER: IN TESTS LED BY DANA-FARBER RESEARCHERS, A NEW BLOOD TEST SCREENED FOR NUMEROUS TYPES OF CANCER WITH A HIGH DEGREE OF ACCURACY. THE TEST USES NEXT-GENERATION TECHNOLOGY TO PROBE DNA WITHIN BLOOD FOR CHEMICAL TAGS CALLED METHYL GROUPS THAT INFLUENCE GENE ACTIVITY. ONE-TIME EDUCATION CLASS FOR CHRONIC INSOMNIA: DANA-FARBER INVESTIGATORS REPORTED THAT A SINGLE-SESSION SLEEP EDUCATION PROGRAM COULD OFTEN CURE CANCER SURVIVORS OF CHRONIC INSOMNIA A COMMON PROBLEM AMONG SURVIVORS AND THAT THOSE WHO DIDNT BENEFIT WERE OFTEN HELPED BY A MORE EXTENSIVE, BUT STILL MODEST, THREE-SESSION PROGRAM. EXPOSURE TO SECOND-HAND VAPOR FROM E-CIGARETTES: A GROWING NUMBER OF MIDDLE- AND HIGH-SCHOOL STUDENTS ARE BEING EXPOSED TO SECOND-HAND AEROSOLS FROM E-CIGARETTES BY LIVING WITH OR BEING AROUND INDIVIDUALS WHO ARE VAPING, ACCORDING TO A DANA-FARBER ANALYSIS OF NATIONAL SURVEY DATA. EXERCISE BENEFITS PATIENTS WITH ADVANCED COLORECTAL CANCER: PATIENTS WITH METASTATIC COLORECTAL CANCER WHO ENGAGED IN MODERATE EXERCISE WHILE UNDERGOING CHEMOTHERAPY TENDED TO HAVE DELAYED PROGRESSION OF THEIR DISEASE AND FEWER SIDE EFFECTS FROM TREATMENT, A STUDY BY DANA-FARBER AND BRIGHAM AND WOMENS HOSPITAL RESEARCHERS FOUND. ARTIFICIAL INTELLIGENCE TOOL SHOWS PROMISE: SCIENTISTS AT DANA-FARBER DEMONSTRATED THAT AN ARTIFICIAL INTELLIGENCE TOOL COULD PERFORM AS WELL AS HUMAN REVIEWERS AND MUCH MORE RAPIDLY IN EXTRACTING CLINICAL INFORMATION ON CHANGES IN TUMORS FROM UNSTRUCTURED RADIOLOGY REPORTS FOR PATIENTS WITH LUNG CANCER. THE TOOL PERFORMED COMPARABLY TO TRAINED HUMAN CURATORS IN DETECTING THE PRESENCE OF CANCER AND ITS RESPONSE TO TREATMENT. IMMUNOTHERAPY AND SECOND DRUG SHOW EFFECTIVENESS IN OVARIAN CANCER: A COMBINATION OF AN IMMUNOTHERAPY DRUG AND A DNA REPAIR-BLOCKING AGENT CAN BE SIGNIFICANTLY MORE EFFECTIVE THAN EITHER DRUG ALONE IN WOMEN WITH HARD-TO-TREAT OVARIAN CANCER, A CLINICAL TRIAL LED BY DANA-FARBER RESEARCHERS INDICATED. THE TRIAL OFFERED EVIDENCE THAT IMMUNOTHERAPIES, WHICH RARELY HAVE AN IMPACT AGAINST OVARIAN CANCER AS SINGLE AGENTS, COULD PRODUCE A POWERFUL ANTI-CANCER RESPONSE IN TANDEM WITH OTHER DRUGS. WALKING SPEED AND OUTCOMES IN OLDER PATIENTS: RESEARCHERS AT DANA-FARBER AND THE VA BOSTON HEALTHCARE SYSTEM UNCOVERED A NEW VITAL SIGN FOR GAUGING SURVIVAL AND LIKELIHOOD OF HAVING AN UNPLANNED HOSPITALIZATION IN OLDER PATIENTS WITH BLOOD CANCERS: THE SPEED AT WHICH THEY CAN WALK. THE RESEARCHERS REPORTED THAT FOR EVERY 0.1 METER PER SECOND DECREASE IN HOW FAST PATIENTS WALK FOUR METERS, THE RISK OF DYING, UNEXPECTEDLY GOING TO THE HOSPITAL, OR USING THE EMERGENCY ROOM ROSE. COMBINATION THERAPY FOR KIDNEY CANCER APPROVED: BASED ON A CLINICAL TRIAL CO-LED BY DANA-FARBER INVESTIGATORS, AN IMMUNOTHERAPY DRUG COMBINATION WON APPROVAL AS A STANDARD FIRST-LINE THERAPY FOR PATIENTS WITH ADVANCED CLEAR CELL RENAL CELL CARCINOMA, THE MOST COMMON FORM OF KIDNEY CANCER. BENEFITS OF HIGH-DOSE VITAMIN D: SUPPLEMENTING CHEMOTHERAPY WITH HIGH DOSES OF VITAMIN D MAY BENEFIT PATIENTS WITH METASTATIC COLORECTAL CANCER BY DELAYING PROGRESSION OF THE DISEASE, A SMALL CLINICAL TRIAL LED BY DANA-FARBER INVESTIGATORS SUGGESTED. LONG-TERM MARIJUANA SMOKING AND PULMONARY DISEASE: HIV-INFECTED MEN WHO SMOKE MARIJUANA FOR SEVERAL YEARS ARE AT HEIGHTENED RISK OF DEVELOPING BOTH INFECTIOUS AND NON-INFECTIOUS LUNG DISEASES, REGARDLESS OF WHETHER THEY ALSO SMOKE TOBACCO PRODUCTS, RESEARCHERS AT DANA-FARBER REPORTED. THE FINDINGS SUGGESTED THAT HEALTHCARE PROVIDERS CAN HAVE AN IMPORTANT ROLE IN REDUCING THE RISK OF CERTAIN LUNG DISEASES IN HIV-POSITIVE PATIENTS BY COUNSELING THEM ABOUT THE POTENTIAL HARM OF MARIJUANA SMOKING ON LUNG HEALTH. 34342333 5367834 COMMUNITY BENEFITS THE ROLE OF DANA-FARBER'S COMMUNITY BENEFITS OFFICE IS TO SUPPORT THE INSTITUTE'S GOAL TO REDUCE CANCER RISK AMONG MEDICALLY UNDERSERVED POPULATIONS. TO THAT END, WE WORK WITH CITY AND STATE HEALTH DEPARTMENTS, COMMUNITY PARTNERS, AND BOSTON-BASED COALITIONS TO ASSESS AND MONITOR THE NEEDS OF LOCAL RESIDENTS WITH RESPECT TO CANCER CONTROL. WE ARE ON THE FRONT LINES OF SUPPORTING AND COLLABORATING ON PROGRAMS DESIGNED TO ELIMINATE DISPARITIES IN BREAST, COLON, SKIN, AND PROSTATE CANCER; EDUCATE DIVERSE POPULATIONS ABOUT TOBACCO CESSATION, HUMAN PAPILLOMAVIRUS (HPV) PREVENTION AND SCREENING, AND CLINICAL TRIALS; AND STRENGTHEN THE SUPPORT SYSTEM FOR MEDICALLY UNDERSERVED POPULATIONS. IN SHORT, WE ARE COMMITTED TO MAKING DANA-FARBER'S CARE AND RESEARCH FINDINGS ARE MORE ACCESSIBLE TO EVERYONE WITHIN AND OUTSIDE ITS WALLS. IN FY 2019: DANA-FARBERS MAMMOGRAPHY SERVICES PROVIDED CLOSE TO 2,400 MAMMOGRAMS ON THE VAN AND AT THE MAMMOGRAPHY SUITE IN ROXBURY. 1,086 INDIVIDUALS RECEIVED BREAST HEALTH EDUCATION ON THE MAMMOGRAPHY VAN OR AT A COMMUNITY OUTREACH EVENT. A TOTAL OF 61 COMMUNITY MEMBERS HAVE BEEN TRAINED AS LAY HEALTH ADVISORS IN BREAST CANCER, SCREENING GUIDELINES, AND HEALTH PROMOTION AND OUTREACH STRATEGIES. 1,659 COMMUNITY MEMBERS WERE REACHED THROUGH SUN SAFETY EDUCATION AND SCREENING EVENTS, WITH AN AVERAGE OF 59 PARTICIPANTS PER EVENT. A TOTAL OF 3,354 INDIVIDUALS WERE REACHED THROUGH 146 COMMUNITY EDUCATION, OUTREACH AND SCREENING EVENTS. 1688904739 true true false true false false false false false true true false false true true false false true false false true false false true true false true true true true true true false false false false false true false false false false true false false false true true true true true false true 734 0 true 6457 true true true true CJ false false false true true false false false false false false X 58 57 true false false false false false false true true false false true true true true true true true true false AL AK AZ CA CO CT DC DE FL GA HI ID IL IN IA KS KY LA ME MH MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VI VA WA WV WI WY X MELISSA CHAMMAS 6175828311 450 BROOKLINE AVE BP418 Boston MA 02115 X Alexander Susan Esq Trustee 1.0 0.0 X 0 0 0 Beale Jeffrey Trustee (TERM ENDED 5/4/19) 1.0 0.0 X 0 0 0 Bekenstein Joshua Trustee & Chairman 2.0 0.0 X X 0 0 0 Berger Harvey MD Trustee 1.0 0.0 X 0 0 0 Berkowitz Roger Trustee 1.0 0.0 X 0 0 0 Berylson Amy Trustee 1.0 0.0 X 0 0 0 Beschloss Afsaneh Trustee 1.0 0.0 X 0 0 0 Blum Betty Ann Trustee 1.0 0.0 X 0 0 0 Brock-Wilson Jane Trustee 1.0 0.0 X 0 0 0 Chandra Monica Trustee 1.0 0.0 X 0 0 0 Cox Howard Trustee 1.0 0.0 X 0 0 0 Curtin Neal Esq Trustee & Secretary 2.0 0.0 X X 0 0 0 DALEY KAREN PHD MPH RN FANN Trustee 1.0 0.0 X 0 0 0 DaSilva Kevin Trustee 1.0 0.0 X 0 0 0 Dobson Sean Trustee 1.0 0.0 X 0 0 0 Farrington Thomas Trustee (TERM ENDED 1/28/19) 1.0 0.0 X 0 0 0 Fine Stephen Trustee 1.0 0.0 X 0 0 0 Gibson Nancy Trustee 1.0 0.0 X 0 0 0 Glimcher Laurie MD Trustee, President and CEO 44.0 6.0 X X 1440948 35655 290345 Greenthal Jill Trustee 1.0 0.0 X 0 0 0 Gross Phillip Trustee 1.0 0.0 X 0 0 0 Hadley Christopher Trustee 1.0 0.0 X 0 0 0 Jaffe Alison Trustee 1.0 0.0 X 0 0 0 Jamieson Jane Trustee 1.0 0.0 X 0 0 0 Janower Andrew Trustee 1.0 0.0 X 0 0 0 Kaplan Andrew Trustee (AS OF 1/28/19) 1.0 0.0 X 0 0 0 Knez Brian Trustee 1.0 0.0 X 0 0 0 Koppel Steven Trustee 1.0 0.0 X 0 0 0 Koster Stephen Esq Trustee 1.0 0.0 X 0 0 0 Kyle Amy Esq Trustee 1.0 0.0 X 0 0 0 LaTorre James Trustee (TERM ENDED 9/20/19) 1.0 0.0 X 0 0 0 Lubin Richard Trustee & Vice-Chairman 2.0 0.0 X X 0 0 0 Lucas Bradley Trustee 1.0 0.0 X 0 0 0 Lucchino Lawrence Trustee 1.0 0.0 X 0 0 0 Marcus Paul Trustee 1.0 0.0 X 0 0 0 Martin Demond Trustee 1.0 0.0 X 0 0 0 McCain Tracey Esq Trustee 1.0 0.0 X 0 0 0 Medel Roger MD Trustee 1.0 0.0 X 0 0 0 Miller Eric PHD Trustee (AS OF 1/28/19) 1.0 0.0 X 0 0 0 Norberg Joseph Trustee 1.0 0.0 X 0 0 0 O'Connor John Trustee & Treasurer 2.0 0.0 X X 0 0 0 Packman Karen Linde Trustee 1.0 0.0 X 0 0 0 Palandjian Peter Trustee 1.0 0.0 X 0 0 0 Pasquarello Theodore Trustee 1.0 0.0 X 0 0 0 Perini Jennifer Trustee 1.0 0.0 X 0 0 0 Perlmutter Steven Esq Trustee 1.0 0.0 X 0 0 0 Poduska Susan Trustee 1.0 0.0 X 0 0 0 Reynolds Robert Trustee 1.0 0.0 X 0 0 0 Sachs Robert Esq Trustee 1.0 0.0 X 0 0 0 Schlager Eric Trustee 1.0 0.0 X 0 0 0 Sen Laura Trustee 1.0 0.0 X 0 0 0 Stansky Robert Trustee 1.0 0.0 X 0 0 0 Stratford Sandra MD MSc Trustee 1.0 0.0 X 0 0 0 Stecher Esta Trustee 1.0 0.0 X 0 0 0 Sullivan Ronald Trustee 1.0 0.0 X 0 0 0 Terrana Beth Trustee 1.0 0.0 X 0 0 0 Ting David Trustee (TERM ENDED 1/28/19) 1.0 0.0 X 0 0 0 Tocio Mary Ann Trustee 1.0 0.0 X 0 0 0 Tuli Sushil Trustee (AS OF 1/28/19) 1.0 0.0 X 0 0 0 Whelan Lori Trustee 1.0 0.0 X 0 0 0 Williams Frederica Trustee 1.0 0.0 X 0 0 0 Yeshwant Krishna Trustee 1.0 0.0 X 0 0 0 Boskey Richard S ESQ Asst. Sec. & general counsel 45.0 5.0 X 593401 0 68586 Puhy Dorothy COO & EVP (UNTIL 3/2/19) 47.0 3.0 X 848026 0 45426 Reney Michael CFO and Asst. Treasurer 46.0 4.0 X 787393 0 45392 Terwilliger James COO & EVP (AS OF 2/18/19) 48.0 2.0 X 0 0 0 Bartel Sylvia RPh MHP VP of Pharmacy Services 50.0 0.0 X 266504 0 72770 Bunnell Craig A MD Chief Medical Officer 50.0 0.0 X 714776 0 45599 DUVAL MELANY SVP OF DEV. (AS OF 12/1/18) 50.0 0.0 X 50000 0 0 Ebert Benjamin MD PHD Chair of Medical Oncology 50.0 0.0 X 685392 0 66180 Gettleman Wendy VP of Facilities Management 50.0 0.0 X 291148 0 72829 Johnson Bruce MD Chief Clinical Research Office 50.0 0.0 X 624131 0 59114 Liebow Elizabeth CHIEF STRATEGY OFFICER 50.0 0.0 X 341986 0 66041 Megdal Maria SVP of Institute Operations 50.0 0.0 X 438333 0 57922 Memmott Drew SVP Research Administration 50.0 0.0 X 419545 0 66104 Paresky Susan SVP OF DEV (UNTIL 1/1/19) 50.0 0.0 X 718396 0 60245 Rollins Barrett J MD PHD Chief Scientific Officer 50.0 0.0 X 647079 0 61263 Constantine Michael MD Milford Med Dir-Hematol Onc 50.0 0.0 X 711035 0 57634 Armstrong Scott MD Chair of Pediatric Oncology 50.0 0.0 X 683486 0 68069 Benz Edward J JR MD President and CEO Emeritus 42.0 8.0 X 1526785 0 56454 WINER ERIC MD SVP CHF CLINICAL STRAT OFFICER 50.0 0.0 X 722984 0 53627 GRIFFIN JAMES D MD PROFESSOR OF MEDICINE 50.0 0.0 X 686369 0 63652 Bird Karen Finance Consultant 50.0 0.0 X 406255 0 33678 Stone Richard M MD PROFESSOR OF MEDICINE 50.0 0.0 X 480429 0 68640 14084401 35655 1479570 1292 true true false Partners Healthcare System Inc PO Box 3715 BOSTON MA 02241 Information Systems 112381381 Brigham and Women's Hospital 75 Francis St BOSTON MA 02115 Medical Services 66950796 BOND BROTHERS 16 Cabot Road Suit 300 MEDFORD MA 02155 Building Contractor 26175642 Brigham and Women's Physicians Org 111 Cypress St BROOKLINE MA 02445 Medical Services 18540869 WALSH BROTHERS INC 200 Commercial Street BOSTON MA 02190 Building Contractor 16918262 475 202556 25227354 149816392 429117118 14483117 604363420 NET PATIENT SERVICE REVENUE 621110 1263292503 1263292503 NETWORK COLLABORATION 900099 7138416 7138416 1270430919 2893131 2893131 0 96094866 96094866 2405132 2405132 0 2405132 2405132 438561 649776 -211215 -211215 -211215 913163 25227354 4518668 -3605505 -3605505 0 0 0 0 0 0 PARKING LOT REVENUE 812930 6073362 6073362 FOOD SERVICE REVENUE 722210 4291088 4291088 WCB BOUTIQUE INCOME 446199 1113069 1113069 1661377 88157 1573220 13138896 1985509644 1270430919 88157 110627148 2750179 2750179 2617655 2617655 0 0 8902713 3279868 4854449 768396 3099838 1166798 1933040 519027848 449037032 45340459 24650357 30476037 19309033 8827814 2339190 13308138 8431781 3854890 1021467 33889716 21471874 9816635 2601207 7780709 5072833 2707649 227 19260032 12055173 7189203 15656 973650 973650 760126 760126 4127668 4127668 0 149557212 128728699 20713579 114934 10395389 8537124 845744 1012521 40727806 34741903 4856599 1129304 63864979 61432412 2393951 38616 0 91935054 69451448 22475390 8216 11302962 10129729 1047209 126024 0 5466345 2094783 2048447 1323115 26769048 26577456 191592 0 87761390 79735346 8026044 5070096 38839 5031257 MEDICAL SUPPLIES 605366919 605366919 MISCELLANEOUS 112830748 110846723 1446536 537489 OTHER PATIENT CARE EXPENSE 25271006 25271006 1883293263 1688904739 154574137 39814387 0 0 178566040 142105787 63138970 98133091 139003733 171535599 509319 689516 0 0 0 0 29714527 35392500 45380890 47670159 1922917252 909588711 955688990 1013328541 0 0 0 0 0 0 7894580 7894580 1470808951 1610347227 2890706000 3127097000 135803630 160016271 0 0 0 0 534438729 516834887 0 0 0 0 72968294 80497845 0 0 392623944 425293729 1135834597 1182642732 X 846457749 968782968 703139823 759256969 205273831 216414331 1754871403 1944454268 2890706000 3127097000 X 102216381 87366484 X false true X true true true X 427883303 453735920 511844582 561378936 604363420 2559206161 0 0 427883303 453735920 511844582 561378936 604363420 2559206161 0 2559206161 17299053 13734456 9251603 9629978 101324433 151239523 68696 68696 14345239 15146613 17212855 23432437 14052058 84189202 2794703582 5094697555 0.91573 0.92166 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true false true false true 627154 true 132972 false false 760126 false Schedule C Part II-B VAN SCOYOC & ASSOCIATES - PROVIDED FEDERAL LEGISLATIVE CONSULTING FOR DFCI. MCDERMOTT, QUILTY & MILLER LLP - PROVIDED STATE LEGISLATIVE AND GOVERNMENT RELATIONS CONSULTING ON HEALTH INTERESTS TO DFCI. CONFERENCE OF BOSTON HOSPITALS PROVIDED STATE AND FEDERAL LOBBYING SUPPORT TO DFCI. ALLIANCE OF DEDICATED CANCER CENTERS REPRESENTS THE NATION'S TEN FREESTANDING CANCER CENTERS. WE WORK TOGETHER ON FEDERAL REGULATORY, LEGISLATIVE AND REIMBURSEMENT ISSUES UNIQUE TO DEDICATED CANCER CENTERS. DFCI IS A MEMBER OF THE AMERICAN HOSPITAL ASSOCIATION AND THE MASSACHUSETTS HOSPITAL ASSOCIATION, NOT-FOR-PROFIT ORGANIZATIONS THAT REPRESENT AND ADVOCATE FOR THE COLLECTIVE INTERESTS OF THEIR MEMBER HOSPITALS AND HEALTH SYSTEMS THROUGH LEADERSHIP IN PUBLIC ADVOCACY, EDUCATION, AND INFORMATION. A PORTION OF THE MEMBERSHIP DUES TO THESE ORGANIZATIONS ARE USED FOR LOBBYING ACTIVITIES. ON OCCASION, DFCI EXECUTIVE LEADERSHIP MEET WITH STATE AND FEDERAL ELECTED OFFICIALS TO ADVOCATE FOR THE PASSAGE OF LEGISLATION AND FUNDING TO ADVANCE CANCER RESEARCH AND TREATMENT, AND LEGISLATION TO SUPPORT SERVICES FOR CANCER PATIENTS AND CANCER SURVIVORS. IN ADDITION, DFCI SUBMITS LETTERS AND/OR TESTIMONY TO ELECTED OFFICIALS AND POLICY MAKERS on these issues. 301578000 11140000 18454000 18152000 313020000 276248000 12288000 30131000 17089000 301578000 252162000 9815000 32600000 18329000 276248000 238449000 10151000 20243000 16681000 252162000 250650000 7603000 -4102000 15702000 238449000 0.69140 0.30860 false true true 7640445 7640445 1233156412 513422293 719734120 167078138 92760235 74317902 413200418 303406183 109794235 101841839 101841839 1013328541 INTEREST IN DANA-FARBER, INC. 1433066609 MISCELLANEOUS ASSETS 134062618 INTEREST IN DFCCN 43218000 1610347227 0 AMOUNTS DUE 3RD PARTY PAYOR 49158582 RESEARCH ADVANCES 119683000 PROV FOR MED MALPRACTICE CLAIM 1399000 SWAP VALUATION LIABILITY 61650000 MISCELLANEOUS LIABILITIES 193403147 425293729 SCHEDULE D, PART V, QUESTION 4 DANA-FARBER, INC. (DFI) A RELATED ORGANIZATION OF DANA-FARBER CANCER INSTITUTE, INC. (THE INSTITUTE) HOLDS THE ENDOWMENTS FOR DFCI AND THEREFORE REPORTS THE ENDOWMENT FUNDS ON DFI'S FORM 990 ACCORDINGLY. AS DESCRIBED IN THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS, THE INSTITUTE'S ENDOWMENTS CONSIST SOLELY OF DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR PURPOSES DIRECTLY RELATED TO THE INSTITUTE'S EXEMPT MISSION AND PURPOSES. AS REQUIRED BY GENERALLY ACCEPTED ACCOUNTING PRINCIPLES, NEW ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OF DONOR-IMPOSED RESTRICTIONS. ALL USES OF THE ORGANIZATION'S ENDOWMENT FUNDS ARE IN FURTHERANCE OF TO THE INSTITUTE'S EXEMPT MISSION AND PURPOSES. Central America and the Caribbean 0 0 Program Services Jointly owned for insu 3352984 Central America and the Caribbean 0 0 Program Services Subcontracted Research 146442 Sub-Saharan Africa 0 0 Program Services Subcontracted Research 1496136 Europe (Including Iceland and Greenland) 0 0 Program Services Subcontracted Research 1114326 East Asia and the Pacific 0 0 Program Services Subcontracted Research 1148429 South Asia 0 0 Program Services Subcontracted Research 306359 Middle East and North Africa 0 0 Program Services Subcontracted Research 172106 South America 0 0 Program Services Subcontracted Research 36690 North America 0 0 Program Services Subcontracted Research 996970 East Asia and the Pacific 0 0 Program Services Research and Education 647208 South America 0 0 Program Services Research and Education 547301 0 0 0 0 9964951 9964951 true false true false false true X X X X X X X true TRUESENSE MARKETING Direct Mail false 15485355 3798309 11687046 Grenzebach Glier Assoc Inc Consulting false 311109 Turnkey Consulting false 18250 15485355 4127668 11687046 All States BMJF Walk 9036972 8863775 173197 257650 37437 3300 1272061 DFMC 6920664 6710564 210100 74580 16022 382702 14 10182881 9653015 529866 605618 65159 481753 1322387 26140517 25227354 913163 937848 118618 485053 2977150 4518669 -3605506 true true X true X true X true true true false true true 23110408 -8916172 14194236 0.00750 78350110 -54326263 24023848 0.01280 101460518 -63242435 38218084 0.02030 5644272 5644272 0.00300 5863397 -683208 5180189 0.00280 671390900 -543655638 127735261 0.06780 2551007 2551007 0.00130 685449576 -544338846 141110729 0.07490 786910094 -607581281 179328813 0.09520 510469 510469 0.00030 412000 412000 0.00020 922469 922469 0.00050 true 297261630 334328986 -37067356 X true true 1 1 DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVE BOSTON MA 02215 www.dana-farber.org X X X D-F/BWH @ Milford, and SOUTH Shore D-F @ st elizabeth's DANA-FARBER CANCER INSTITUTE INC 1 false false true X X X X X X X X X 18 true false false true X dana-farber.org X true 18 true dana-farber.org false true X 150. 300. X true true X X X true X dana-farber.org/PFA X dana-farber.org/PFA X dana-farber.org/PFA X X X X X X true X false X X X true X false false Part V, SECTION B, Line 5 In September 2019, Dana-Farber's Board of Trustees approved the 2020-2023 Cancer-Focused Community Health Needs Assessment (CHNA) and Implementation Plan to ensure that our collective efforts have the maximum possible impact within the Institute's priority neighborhoods. Dana-Farber's Community Benefits Office retained Health Resources in Action (HRiA), a non-profit public health consultancy organization in Boston, to undertake a comprehensive assessment of the health needs within our priority communities, including how those needs are currently being addressed and where there are opportunities to address these needs in the future. Dana-Farber's 2020-2023 Cancer CHNA builds off of information gathered for Boston's first large-scale collaborative city-wide Community Health Needs Assessment in which target neighborhoods such as Dorchester, Roxbury, Jamaica Plain, Mission Hill, and Mattapan were investigated thoroughly. The purpose of the CHNA is to advance community efforts and priority areas by: assessing cancer burden in the community as well as access to and availability of cancer-related services; identifying key areas of significant community need and vulnerable populations; examining the impact and role of social determinants of health; and facilitating the development of multi-year implementation strategies to guide the hospitals' community health initiatives and community investments. In addition to identifying broad health issues facing residents, the 2019 CHNA investigates the full continuum of cancer care; it explores different aspects of care from initial screening, to treatment, and culminates with considerations of survivorship. The Boston CHNA-CHIP Collaborative is a new initiative that was created and launched by a number of stakeholders-community organizations, health centers, community development corporations, hospitals, and the Boston Public Health Commission. It aims to undertake the first large-scale collaborative city-wide Community Health Needs Assessment (Boston CHNA) and Community Health Improvement Planning (Boston CHIP) process. The goals of the Boston CHNA are to: Systematically identify the health-related needs, strengths, and resources of communities to inform future planning Understand the current health status of Boston overall and its sub-populations within their social context, and Meet regulatory requirements for a number of institutions, organizations, and agencies (e.g. IRS requirements for non-profit hospitals, PHAB for health departments). During the city-wide CHNA: As a member of the steering committee and Co-Chair of the Community Engagement Work Group, Dana-Farber worked closely with members of the Boston CHNA/CHIP Collaborative to conduct a robust data collection and engagement process for the Boston CHNA. Citywide survey administered online and in-person in 7 languages (English, Spanish, Portuguese, Haitian Creole, Chinese, Vietnamese, and Arabic), engaging over 90 organizations and over 2,400 Boston residents, with a focus on targeting hard to reach populations not typically represented. A total of 13 focus groups were conducted with specific populations, 45 interviews were held with organizational and community leaders across various sectors to gauge their perceptions of community needs, strengths, and opportunities. Sectors represented in these interviews included: public health, health care, housing and homelessness, transportation, community development, faith, education, public safety, environmental justice, government, workforce development, social services, food insecurity, and business organizational staff that work with specific population such as youth, seniors, disabled, LGBTQ, and immigrants. During the Cancer CHNA: 8 focus groups were conducted with adult cancer patients in active treatment, survivors, and caregivers in English, Spanish, and Chinese. 7 cancer-specific key informant interviews were held with cancer representatives from roles related to primary care, patient navigation and advocacy. Key informants represented a number of sectors including academic research, health care, public health, social service, and city government. Discussions explored participants' perceptions of their communities, priority health concerns, perceptions of cancer and related services across the cancer continuum (prevention, screening, treatment, survivorship), and suggestions for future services and resources to address these issues. The strategies and goals outlined in our 2020-2023 CHNA Implementation Plan are a natural continuation of the efforts identified in our 2016-2019 Plan and are designed to advance and strengthen our existing community-based initiatives while also seeking to address the social determinants of health through collaborative partnerships. PART V, LINE 7A DFCI's Community Health Needs Assessment Report is available on the DFCI Website. http://www.dana-farber.org/About-Us/Community-Outreach/Community-Health- Needs-Assessment-Reporting.aspx PART V, LINE 10A DFCI's implementation strategy is available on the DFCI website. http://www.dana-farber.org/uploadedFiles/Library/about-us/community- outreach/chna-implementation-plan.pdf Part V, Line 11 Dana-Farber Cancer Institute addressed all the needs identified in the Community Health Needs Assessment and the accompanying Implementation Plan. A full description of our programs is available on our website both in the Community Health Needs Assessment Report and in the Community Health Implementation Plan. While our expertise as a comprehensive cancer center leads us to focus largely on reducing cancer incidence and mortality among medically underserved populations through our clinical community screening and outreach programs that include mobile mammography and breast health education, skin cancer education and screening, HPV education and vaccination, tobacco cessation and increasing awareness about survivorship in communities of color, we recognize that our priority neighborhoods are also dealing disproportionately with challenging situations related to social and economic factors such as limited employment opportunities, substance abuse and opioid addiction, low education levels, lack of affordable housing, and community violence, among others. We work on these broader issues by advocating and by partnering with local coalitions and community based organizations such as Boston Alliance for Community Health and member organizations. PART V, LINE 22 Depending on a patient's financial situation, FAP-eligible patients were charged between 0% to 30% of billed charges, which was not more than the AGB. In FY19, DFCI determined AGB on an annual basis using the "look-back method," described under Treasury Regulation Section 1.501(r)-5(b)(1). Specifically, DFCI's annual AGB percentage was equal to sum of all gross charges during the prior fiscal year divided by Claims Paid in connection with those charges. For purposes of the AGB calculation, Claims Paid included claims for emergency and medically necessary care paid by both Medicare fee-for-service and all private health insurers as primary payers, together with any associated portions of these claims paid by Medicare beneficiaries or insured individuals in the form of co-payments, co-insurance or deductibles. 1 DANA-FARBERNHOH ELLIOTT MED CENTER 40 BUTTRICK RD LONDONDERRY NH 03053 MED ONCOLOGY & INFUSION UNIT Part I, Line 3c In addition to determining eligibility for discounted care based on family income, DFCI offers assistance to patients who have excessive medical bills (exceeding 30-40% of family income). Part I, Line 6a The community benefit report was completed by DFCI and is annually provided to the Massachusetts Attorney General's office, where it is then made public on its website. Part I, Line 7 DFCI's State Cost Report was used to develop the institute's cost to charge ratio that was applied to charity care charges to determine the cost of financial assistance (Line 7A). Line 7B reflects the specific loss incurred for the institute's Medicaid activity. The Institution is a preeminent provider of health training to health professionals who desire training in the skills necessary to treat cancer patients. The institution trains physicians, scientists, medical students and individuals looking to create a career in the field of cancer. The amount reported as Health Training represent costs in excess of amounts reimbursed by third party payers such as training grant revenues and direct medical education payments from the Medicare Program. Department leaders submit expenditures to Community Benefits along with a description of the services provided to medically underserved populations. Line 7f expenditures are reviewed by leadership and in partnership with DFCI's Office of Finance, the expenditures are approved. The amounts are captured in three buckets - CB expenditures (all programs); leveraged fund (those funds supported in full or part through grants/donations) and Community Sponsorships. Part II, Line 1 Physical Improvements and housing-DFCI provides a limited number of low cost rooms that serve as a home away from home for oncology patients and their families while they are receiving treatment. Part II, Line 8 To encourage underrepresented students of color to explore and pursue careers in health and science, Dana-Farber maintains educational partnerships with Boston area high schools and colleges. During academic year 2018-2019, 22 students participated in a college and career readiness training program. An additional 62 students were enrolled during the 2019 summer jobs program at Dana-Farber. Eligible students either attended or graduated from Boston public schools. During the 7-week summer program, students interned 30 hours per week and participated in college tours and career readiness workshops. Part III, LINE 8 The Medicare cost on line 6 comes from the Medicare Cost Report and is based on Medicare's cost finding principles and methodologies. We strongly believe that the entire amount of the shortfall of $37,067,356 should be treated as a community benefit as this represents the Institute's commitment to the elderly and disabled community by providing services that are not reimbursed. Part III, Line 9b Within DFCI's credit and collections policy there are provisions that describe collection practices to be followed for patients who are known to qualify for charity care or financial assistance in accordance with federal and Massachusetts law. Part V, Section A DFCI main campus is at 450 Brookline Ave., Boston, MA. DFCI's satellite locations (below) each operate under the same hospital license. Dana-Farber/Brigham and Women's Cancer Center at Milford Hospital 20 Prospect Street, Milford, MA 01757 Dana-Farber/Brigham and Women's Cancer Center at South Shore Hospital 101 Columbian Street, South Weymouth, MA 02190 Dana-Farber at St. Elizabeth's Medical Center 736 Cambridge Street, Cushing Pavilion, 5th Floor, Brighton MA 02135. Part VI, Line 2 Dana-Farber Cancer Institute continuously assesses the community needs through our participation in community coalitions, task forces, working groups and direct communication with the community residents that serve on our external advisory committee and in our patient and family advisory board. A full description of our community engagement process can be found on our website both in the Community Health Needs Assessment Report and in the Community Health Implementation Plan. Part VI, Line 3 DFCI is committed to offering financial assistance to eligible Patients who do not have the ability to pay for their medical services in whole or in part. In order to accomplish this charitable goal, DFCI widely publicizes its Patient Financial Assistance (PFA) Policy within its facilities, in direct communications with Patients and in the communities that it services, particularly in the communities with the greatest unmet health needs. The PFA Policy, a plain language PFA summary and the PFA application are posted on DFCI's website in English and Spanish. In addition, information about the PFA is provided to all patients at Registration and/or Admission, and is available upon request, without charge, through a DFCI Financial Counselor, Customer Service Representative, or by mail. Following care, all billing statements sent to a patient indicate how the patient can obtain information about the PFA Policy. In collaboration with DFCI's community partners, information about the FAP is shared with residents of DFCI's priority neighborhoods. Efforts to notify community members most likely to require assistance include distributing plain language summaries of this Policy to local community health centers and other non-profit organizations. Part VI, Line 4 DFCI serves the community of Eastern Massachusetts and New England, including the communities surrounding its primary location in Boston and its satellite locations in Milford, Massachusetts, Weymouth, Massachusetts, Brighton, Massachusetts and Londonderry, New Hampshire. DFCI's community includes adults and children with cancer or at risk of developing cancer, and their families. DFCI focuses its community outreach efforts on its priority Boston neighborhoods of Roxbury, Mission Hill, Dorchester, Mattapan and Jamaica Plain (which collectively comprise 39% of Boston's overall population). Two of Boston's most populated neighborhoods are DFCI's priority neighborhoods-Dorchester with 122,598 residents, followed by Roxbury with 49,028. White residents now make up less than half of the city's racial and ethnic composition (46%). Black or African American residents were the second largest racial and ethnic group (23%), followed by Hispanics (18%) and Asians (9%). There is substantial variation in the racial and ethnic diversity by DFCI priority neighborhood, with nearly three-quarters of Mattapan residents and half of Roxbury residents identifying as Black or African American. Among DFCI priority neighborhoods, Roxbury and Jamaica Plain have the largest Hispanic populations with 29% and 24% respectively, while Mission Hill and Dorchester have the largest Asian populations among the priority neighborhoods with 14% and 10% respectively. The median incomes of DFCI's priority communities are generally much lower than Boston overall, with Roxbury at a median income of $25,254, Mission Hill at $35,020, and Mattapan at $42,206. Many of DFCI's priority neighborhoods, Roxbury and Mattapan, are more likely to have a greater population at the lower end of the income spectrum. Residents in DFCI's priority neighborhoods appear to experience higher rates of poverty than Boston overall. Female headed households are especially vulnerable, with 45% of Roxbury female-headed households living below the poverty line. Despite its statewide reach and services provided through our satellite operations in Weymouth, Allston/Brighton, and Milford, Dana-Farber's prioritization of these five neighborhoods within its local service area reflects a commitment to reducing disparities in cancer care and improving the health and well-being of neighborhood residents. Through our collaborative approach, the satellite locations have agreed to leverage each other's cancer control expertise to expand and strengthen our programs such as bringing cancer prevention efforts in Spanish to the Weymouth Area. The Allston/Brighton satellites have also mutually agreed to continue to work together to strengthen mammography screening rates through our partnership with the local community health center and to explore other opportunities to have greater impact on the health and well-being of local residents. Dana-Farber also aims to prioritize populations disproportionately impacted by cancer, including diverse racial and ethnic populations, individuals from low socioeconomic backgrounds, and immigrants. Based on the CHNA data, the populations below appear to have disproportionately higher levels of disease risk and burden, warranting increased attention. Part VI, Line 5 Dana-Farber's 2020-2023 Community Health Needs Assessment and Implementation Plan provide a robust description of our comprehensive cancer control programs and services. The report also provides a summary of accomplishments from our last needs assessment and sets forth our commitment to addressing the new opportunities to reduce the cancer burden in medically underserved communities in Boston. The reports can be found at http://www.dana-farber.org/About-Us/Community-Outreach/Community-Health-Ne eds-Assessment-Reporting.aspx. In addition, DFCI furthers its exempt purpose by promoting the health of the community through devoting the vast majority of its surplus funds to institutional supported research (128 million), by providing financial assistance to patients unable to afford care and by maintaining a community board. Part VI, Line 7 State Filing of Community Benefit Report Massachusetts State Filing of Community Benefit Report Massachusetts. PART VI, SUPPLEMENTAL INFORMATION 501(r) Reporting under IRS Revenue Procedure 2015-21 During FY19, DFCI determined that its FAP should be clarified to more clearly address the treatment of deductibles determined and required by the state Health Safety Net program, in order to ensure that FAP-eligible individuals are not charged more than AGB for medically necessary services. The amended FAP was adopted and implemented on 9/10/2019 and has been widely publicized within the meaning of Treas. Reg. 1.501(r)-4(b)(5). true Harvard University 60 Oxford St Cambridge MA 02138 042103580 501(C)(3) 1241004 CANCER RES AND DEVLP City of Boston City Hall Plaxa Boston MA 02114 046001380 115 974128 Community Prtnrship Whittier Street Health Center 1125 TREMONT STREET ROXBURY MA 02120 042619517 501(C)(3) 154270 CANCER RES AND DEVLP Friends of Dana-Farber 450 Brookline Ave BOSTON MA 02215 371613621 501(C)(3) 50000 CANCER RES AND DEVLP Leukemia & Lymphoma Society Inc 1311 MAMARONECK AV WHITE PLANES NY 10605 135644916 501(C)(3) 40000 CANCER RES AND DEVLP PROSTATE HEALTH EDUCATION NETWORK INC 500 Victory Rd 4th FL Quincy MA 02453 331042404 501(C)(3) 30000 CANCER RES AND DEVLP National Assoc of Corp Directors New England Ch 62 Deep MDW Exeter NH 03833 043370584 501(C)(3) 25000 Community Support Fenway High School 174 Ipswich St BOSTON MA 02215 046719813 501(C)(3) 20000 Community Support Camp Harbor View 200 Clarendon St 60th FL Boston MA 02116 753235491 501(C)(3) 15000 Community Support United Way of Massachusetts Bay 51 Sleeper St Boston MA 02210 042382233 501(C)(3) 13500 Community Support Boston Public Health Commission 1010 Massachusetts Ave Boston MA 02118 043316655 115 10000 Community Support Health Care for All Inc One Federal Streeet Boston MA 02110 043071598 501(C)(3) 10000 Community Support The Colorectal Cancer Alliance 1024 Vermont AV NW 1066 Washington DC 20005 860947831 501(C)(3) 10000 CANCER RES AND DEVLP THE BREAST CANCER RESEARCH FOUNDATION 60 EAST 56TH ST 8TH FL NEW YORK NY 10022 133727250 501(C)(3) 10000 CANCER RES AND DEVLP 12 2 Patient Assistance 21 14197 Patient Assistance 3241 2603458 FMV ASST LIVING & TRAVEL Part IV ALL GRANTS AND DONATIONS WERE GIVEN TO 501(C)(3) ORGANIZATIONS TO FULFILL THEIR MISSIONS. X false true X X X X X false true false false false false false true false Glimcher Laurie MD Trustee, President and CEO 1140233 35655 173019 0 127696 0 277441 0 12904 0 1731293 35655 0 0 Boskey Richard S ESQ Asst. Sec. & general counsel 513146 0 38232 0 42023 0 38955 0 29631 0 661987 0 0 0 Puhy Dorothy COO & EVP (UNTIL 3/2/19) 702139 0 77564 0 68323 0 38955 0 6471 0 893452 0 0 0 Reney Michael CFO and Asst. Treasurer 642739 0 46807 0 97847 0 38955 0 6437 0 832785 0 0 0 Bird Karen Finance Consultant 401307 0 0 0 4948 0 0 0 33678 0 439933 0 0 0 Bartel Sylvia RPh MHP VP of Pharmacy Services 249806 0 10924 0 5774 0 36819 0 35951 0 339274 0 0 0 Bunnell Craig A MD Chief Medical Officer 612212 0 55461 0 47103 0 38955 0 6644 0 760375 0 0 0 DUVAL MELANY SVP OF DEV. (AS OF 12/1/18) 0 0 50000 0 0 0 0 0 0 0 50000 0 0 0 Ebert Benjamin MD PHD Chair of Medical Oncology 524143 0 127500 0 33749 0 38955 0 27225 0 751572 0 0 0 Gettleman Wendy VP of Facilities Management 278098 0 11995 0 1055 0 38652 0 34177 0 363977 0 0 0 Johnson Bruce MD Chief Clinical Research Office 525454 0 45902 0 52775 0 37314 0 21800 0 683245 0 0 0 Liebow Elizabeth CHIEF STRATEGY OFFICER 312544 0 22866 0 6576 0 38955 0 27086 0 408027 0 0 0 Megdal Maria SVP of Institute Operations 392386 0 29124 0 16823 0 38955 0 18967 0 496255 0 0 0 Memmott Drew SVP Research Administration 376538 0 28060 0 14947 0 38955 0 27149 0 485649 0 0 0 Paresky Susan SVP OF DEV (UNTIL 1/1/19) 616834 0 44582 0 56980 0 38955 0 21290 0 778641 0 0 0 Rollins Barrett J MD PHD Chief Scientific Officer 557284 0 41391 0 48404 0 38955 0 22308 0 708342 0 0 0 Stone Richard M MD PROFESSOR OF MEDICINE 419735 0 30905 0 29789 0 38955 0 29685 0 549069 0 0 0 Constantine Michael MD Milford Med Dir-Hematol Onc 616340 0 46458 0 48237 0 25205 0 32429 0 768669 0 0 0 Armstrong Scott MD Chair of Pediatric Oncology 555328 0 89116 0 39042 0 38955 0 29114 0 751555 0 0 0 Benz Edward J JR MD President and CEO Emeritus 944229 0 0 0 582556 0 38955 0 17499 0 1583239 0 0 0 WINER ERIC MD SVP CHF CLINICAL STRAT OFFICER 560218 0 70532 0 92234 0 38955 0 14672 0 776611 0 0 0 GRIFFIN JAMES D MD PROFESSOR OF MEDICINE 587759 0 43635 0 54975 0 38955 0 24697 0 750021 0 0 0 SCHEDULE J, PART I, LINE 4B THE FOLLOWING INDIVIDUALS PARTICIPATE IN DFCI'S 457(F) PLAN; TAXABLE AMOUNTS ARE INCLUDED IN REPORTABLE COMPENSATION IN SCHEDULE J, PART II, COLUMN (B)(III): Armstrong, Scott 35,942 Benz, Edward J. Jr., MD 83,992 Boskey, Richard S., ESQ 30,852 Bunnell, Craig A. MD 42,593 Constantine, Michael, MD 43,660 Ebert, Benjamin 31,906 Glimcher, Laurie MD 113,218 Griffin, James D., MD 40,070 Johnson, Bruce MD 31,906 Liebow, Elizabeth 5,412 Megdal, Maria 15,313 Memmott, Drew 13,498 Paresky, Susan 43,546 Puhy, Dorothy 53,846 Reney, Michael 95,306 Rollins, Barrett J., MD, PHD 36,242 Stone, Richard M MD 19,188 Winer, Eric, MD 36,459 SCHEDULE J, PART I, LINE 7 DURING THE YEAR, THE CEO, COO, CFO, GENERAL COUNSEL AND CERTAIN KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES WERE ELIGIBLE TO RECEIVE AN INCENTIVE PAYMENT, A PORTION OF WHICH HAS A NON-FIXED PAYMENT PAYABLE AT THE DISCRETION OF THE CEO AND IN THE CASE OF THE CEO, THE BOARD OF TRUSTEES, IF THE ORGANIZATION MEETS CERTAIN FINANCIAL PERFORMANCE GOALS. THE MAXIMUM NON-FIXED PORTION OF THESE INCENTIVE PAYMENTS IS BETWEEN 8% (CEO - 40% MAX, OF THAT 32% TEAM, 8% INDIVIDUAL) AND 4% (SVP - 20% MAX, OF THAT 16% TEAM AND 4% INDIVIDUAL; VP - 10% MAX, OF THAT 6% TEAM AND 4% INDIVIDUAL) OTHER REPORTABLE COMPENSATION INCLUDES CURRENT YEAR VESTING AMOUNTS IN DANA-FARBER INSTITUTE'S SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. COMPENSATION FOR KAREN BIRD, FORMER CHIEF FINANCIAL OFFICER, IS PRIMARILY DERIVED FROM HER WORK AS EXECUTIVE DIRECTOR OF THE ALLIANCE OF DEDICATED CANCER CENTERS (ADCC). THE ADCC FULLY REIMBURSES DANA-FARBER CANCER INSTITUTE, INC FOR HER COMPENSATION AND BENEFITS RELATED TO HER WORK AT ADCC. THE REMAINDER OF HER COMPENSATION IS DERIVED FROM HER WORK AS A SENIOR POLICY ADVISOR FOR DANA-FARBER CANCER INSTITUTE, INC. A Massachusetts Development Finance Agency 042456011 57586CZ24 2008-05-22 236234840 See Part VI true false false B Massachusetts Development Finance Agency 043431814 2012-07-02 57500000 See Part VI false false false C Massachusetts Development Finance Agency 043431814 2015-08-03 92500000 See Part VI false false false D Massachusetts Development Finance Agency 043431814 2016-06-23 281786480 See Part VI false false false A 150000000 71025000 302247871 11471 4119476 0 2015100 116494 0 90335422 205649908 0 2011 true false true true B 0 0 57500000 0 0 0 0 0 0 0 57500000 0 2012 true false true true C 0 0 92500000 0 0 0 0 0 0 0 92500000 0 2015 true false true true D 0 0 282856392 0 1655104 0 2486701 0 0 282856392 0 0 2019 false false true true A false false true true true true 0.00000 0.00000 0.00000 false false false true B false false true true true true 0.00000 0.00000 0.00000 false false false true C false false true true true true 0.00000 0.00000 0.00000 false false false true D false false false true true 0.00000 0.00000 0.00000 false false false true A false false false true true true MORGAN STANLEY 39.8 false false true TRINITY FUNDING 2.8 true false true B false false false true true true MORGAN STANLEY 39.8 false false false 0 false true C false false false true true true MORRGAN STANLEY 39.8 false false false 0 false true D false false false true false false 0 false 0 false true A true B true C true D true Part I (Bond Issues): A (a) Issuer name: Massachusetts Health and Educational Facilities Authority, succeeded by Massachusetts Development Finance Agency A (f) Description of purpose: The bond issue was used to refund Pool J-1 issued on June 30, 1993; Pool J-2 issued on June 8, 1995;Pool M-2 issued on May 30, 2002; Series H issued on May 4, 2004; Series I issued on February 8, 2007 and to partially finance the construction of the Yawkey Center for Cancer Care. A (g) Defeased: Issuance A consisted of Series L and Series K. DFCI has refunded the $71,025,000 outstanding principal amount of Series K bonds, which Bonds were defeased and paid, together with accrued interest thereon, on September 3, 2019. B (f) Description of purpose: The bond issue was used to refund part of Series L-2 bonds issued on 5/22/2008. C (f) Description of purpose: The bond issue was used to refund Series L-1 bonds issued on 5/22/2008. D (f) Description of purpose: The bond issue was used to partially cover the acquisition and fit-out of research space and vivarium at the Longwood Center; to partially cover the replacement of HVAC system at the Smith Building; to cover the relocation to, reconstruction and equipping of the Institute's Cell Manipulation Core Facility; and to cover the costs of bond issuance and interest during the construction period as well as other capital projects. E (f) Description of purpose: The bond issue was used to refund Series K bonds issued on 5/22/2008. Part IV (Arbitrage): A 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2019 B 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2019 C 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2019 D 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2019 E 2(c) Did the following apply "No rebate due" - rebate calculation was performed in October 2019 A 4(b) Name of provider: Morgan Stanley Capital Services, Inc. B 4(b) Name of provider: Morgan Stanley Capital Services, Inc. C 4(b) Name of provider: Morgan Stanley Capital Services, Inc. A 5(b) Name of provider: Trinity Funding Company, LLC Benjamin Ebert Employee Housing Loan X 500000 433333 false true true Melany Duval Employee Housing Loan X 150000 138750 false true true Drew Memmott Employee Housing Loan X 75000 35625 false true true Karen Bird Employee Tuition Assistance X 49550 11764 false true true 619472 X 635770 Letter from Donor X 298 13132012 Fair Market Value X 29 350656 Letter from Donor X Miscellaneous 11 364679 Letter from Donor false true false Schedule M, Part I, Line 33 DFCI received donations of art, books, and other goods that it displays in its properties. These goods have values that are either nominal or are not readily determinable and are, therefore, not included as revenue. PART VI, QUESTION 2 FAMILY RELATIONSHIP: JOHN O'CONNOR AND LAURA SEN BUSINESS RELATIONSHIPS: RICHARD LUBIN, CHRISTOPHER HADLEY AND JANE BROCK-WILSON; JOSH BEKENSTEIN AND ANDREW KAPLAN. PART VI, QUESTION 11 PROCESS USED TO REVIEW THE FORM 990 THE DANA-FARBER CANCER INSTITUTE TAX DEPARTMENT PROVIDES ALL FINANCIAL ANALYSIS AND OTHER INFORMATION TO BE INCLUDED ON THE TAX RETURN TO ITS EXTERNAL TAX PREPARER, ERNST & YOUNG LLP, WHICH PREPARES THE DRAFT RETURN. THE DRAFT RETURN IS THEN REVIEWED BY THE DFCI TAX MANAGER, AS WELL AS THE DFCI OFFICE OF GENERAL COUNSEL AND SENIOR MANAGEMENT, BEFORE IT IS SUBMITTED FOR DFCI AUDIT COMMITTEE REVIEW. AFTER THE AUDIT COMMITTEE REVIEWS THE TAX RETURN, AN ELECTRONIC MESSAGE IS SENT TO ALL BOARD MEMBERS WITH A SECURE LINK TO THE TAX RETURN. THE BOARD HAS THE OPPORTUNITY TO REVIEW THE RETURN AND BRING ANY ISSUES TO THE ATTENTION OF THE APPROPRIATE EXECUTIVE MANAGEMENT INDIVIDUALS. A FINAL VERSION OF THE FORM IS APPROVED BY THE CFO AND FILED ELECTRONICALLY BY ERNST & YOUNG LLP WITH THE IRS. PART VI, QUESTION 12C MONITORING & ENFORCEMENT OF CONFLICT OF INTEREST POLICY THE OFFICE OF GENERAL COUNSEL AND THE TAX DEPARTMENT DRAFT A CONFLICT OF INTEREST DISCLOSURE QUESTIONNAIRE EACH YEAR AND REQUIRES THAT ALL TRUSTEES, OFFICERS, AND KEY EMPLOYEES FILL OUT A QUESTIONNAIRE IN ORDER TO IDENTIFY POTENTIAL DISCLOSURES FOR DFCI'S RETURNS. THE OFFICE OF GENERAL COUNSEL COMPILES THE LIST OF DISCLOSURES AND GATHERS FINANCIAL DATA FROM THE ACCOUNTS PAYABLE AND PAYROLL DEPARTMENT FOR ALL ORGANIZATIONS, EMPLOYEES, INDEPENDENT CONTRACTORS, AND OTHER MISCELLANEOUS TRANSACTIONS WHICH WERE DISCLOSED BY ALL INDIVIDUALS. ONCE ALL OF THIS INFORMATION IS COMPILED, THE OFFICE OF GENERAL COUNSEL AND THE TAX DEPARTMENT GOES THROUGH EACH TRANSACTION AND DISCLOSURE TO DETERMINE WHAT NEEDS TO BE DISCLOSED ON THE TAX RETURN. THE TAX DEPARTMENT AND THE OFFICE OF GENERAL COUNSEL ALSO DISCUSSES IF THERE ARE ANY OTHER KNOWN TRANSACTIONS THAT HAVE NOT BEEN DISCLOSED. IF THERE ARE ANY QUESTIONS REGARDING SUCH SITUATION, THE OFFICE OF GENERAL COUNSEL WILL DISCUSS THE QUESTIONS WITH THE INDIVIDUAL TRUSTEES, OFFICERS AND KEY EMPLOYEES INVOLVED. IN ADDITION, THE PROCESS DESCRIBED ABOVE, THE GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS ANNUALLY REVIEWS ANY NEW CONFLICT OF INTEREST DISCLOSURES AND THEY ADDRESS ANY ISSUES THAT MAY ARISE. THE GOVERNANCE COMMITTEE IS ALSO RESPONSIBLE TO BRING ANY MAJOR ISSUES RELATED TO THE CONFLICT OF INTEREST POLICY TO THE EXECUTIVE COMMITTEE AND THE ENTIRE BOARD IF DEEMED NECESSARY. PER DFCI'S CONFLICT OF INTEREST POLICY, IN ORDER TO AVOID A CONFLICT OF INTEREST OR AN APPEARANCE OF A CONFLICT OF INTEREST: 1. A TRUSTEE SHOULD NOT PARTICIPATE IN A VOTE ON A TRANSACTION IN WHICH THE TRUSTEE OR FAMILY MEMBER HAS A FINANCIAL INTEREST AND SHOULD DISCLOSE ANY POTENTIAL CONFLICT BEFORE DFCI ACTS ON THE TRANSACTION. 2. A TRUSTEE, A MEMBER OF HIS OR HER FAMILY, OR AN ENTITY WITH WHICH ONE OR MORE OF THEM HAS A MATERIAL INTEREST, MAY NOT DO BUSINESS WITH DFCI UNLESS EXPRESSLY AUTHORIZED BY DFCI AFTER FULL DISCLOSURE. 3. A TRUSTEE SHOULD FULLY DISCLOSE HIS OR HER ASSOCIATION (INCLUDING EMPLOYMENT, CONSULTING, OR MEMBERSHIP ON A GOVERNING BOARD BY THE TRUSTEE OR A FAMILY MEMBER) WITH AN ENTITY THAT COMPETES WITH OR HAS INTERESTS CONFLICTING WITH THOSE OF DFCI AND SHOULD REFRAIN FROM PARTICIPATING IN ANY VOTE IF THE VOTE AFFECTS DFCI. ONCE A DISCLOSURE HAS BEEN MADE, DFCI'S OFFICE OF GENERAL COUNSEL REVIEWS SUCH CONFLICT WITH THE CHAIR OF THE BOARD WHO DETERMINES IF A CONFLICT EXISTS. WHEN A CONFLICT EXISTS, THE APPROPRIATE COMMITTEE OF THE BOARD OF TRUSTEES DETERMINES IF A MORE ADVANTAGEOUS ALTERNATIVE WITHOUT A CONFLICT OF INTEREST EXISTS AND WHETHER ENTERING INTO THE ARRANGEMENT IS IN THE BEST INTEREST OF DANA-FARBER. PART VI, QUESTION 15A PROCESS FOR DETERMINING COMPENSATION OF PRESIDENT PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES REVIEWS THE PRESIDENT'S (DFCI'S CHIEF EXECUTIVE OFFICER) PERFORMANCE AND MAKES A RECOMMENDATION REGARDING COMPENSATION TO THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ACTS ON THE RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE BI-ANNUALLY COMMISSIONS AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE DECISION OF THE EXECUTIVE COMMITTEE IS REPORTED TO THE FULL BOARD. ANNUALLY, FOLLOWING THE FILING OF FORM 990, DFCI COMPARES THE INFORMATION IT REPORTS FOR ITS PRESIDENT TO THE COMPENSATION OF PRESIDENTS/CEO'S AT OTHER AREA HEALTHCARE ORGANIZATIONS AS WELL AS OTHER INSTITUTIONS THAT ARE CONSIDERED DESIGNATED COMPREHENSIVE CANCER CENTERS. THE BOARD COMPLETED THIS PROCESS AS OF MAY 2019. PART VI, QUESTION 15B PROCESS FOR DETERMINING COMPENSATION OF OFFICERS AND KEY EMPLOYEES PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE DFCI PRESIDENT REVIEWS THE PERFORMANCE OF OFFICERS AND KEY EMPLOYEES AND MAKES A RECOMMENDATION AS TO THEIR COMPENSATION TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES COMPENSATION FOR THOSE INDIVIDUALS BASED ON THAT RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE BI-ANNUALLY RECEIVES THE REPORT OF AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE APPROVAL OF THE COMPENSATION COMMITTEE IS REPORTED TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES AND TO THE FULL BOARD. ANNUALLY, FOLLOWING THE FILING OF FORM 990S DFCI COMPARES THE COMPENSATION OF THESE INDIVIDUALS WITH THOSE AT OTHER AREA HEALTHCARE ORGANIZATIONS AS WELL AS OTHER INSTITUTIONS THAT ARE CONSIDERED DESIGNATED CANCER CENTERS. THE BOARD COMPLETED THIS PROCESS AS OF MAY 2019. PART VI, QUESTION 19 AVAILABILITY OF GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS TO THE PUBLIC WE CURRENTLY PROVIDE THE GOVERNING DOCUMENTS UPON REQUEST. THE GOVERNING DOCUMENTS ARE ALSO AVAILABLE TO THE PUBLIC ON THE SECRETARY OF THE COMMONWEALTH'S WEBSITE. CONFLICT OF INTEREST POLICY - DANA-FARBER CANCER INSTITUTE'S BOARD OF TRUSTEES CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS - THE ORGANIZATION USES THE SERVICES OF DIGITAL ASSURANCE CERTIFICATION LLC (DAC) TO REPORT ANNUAL AUDITED FINANCIAL STATEMENTS AND OTHER RELEVANT ORGANIZATIONAL INFORMATION AS REQUIRED BY CERTAIN REGULATORY AND TAX LAWS. DAC IS A WEBSITE (WWW.DACBOND.COM) FREE TO THE PUBLIC THAT PUBLISHES TAX-EXEMPT BOND ISSUERS' FINANCIAL AND LEGAL DOCUMENTS SUCH AS THE AUDITED FINANCIAL STATEMENTS. FISCAL YEAR 2001 THROUGH THE LATEST ISSUE DATE OF THE AUDITED FINANCIAL STATEMENTS FOR DANA-FARBER CANCER INSTITUTE, INC. CAN BE FOUND ON THE DAC WEBSITE. PART VII, SECTION B THE AMOUNT PAID TO BOND BROTHERS AND WALSH BROTHERS, INC. INCLUDED COSTS FOR BUILDING SERVICES AND MATERIALS. HOWEVER, THE ORGANIZATION WAS UNABLE TO OBTAIN INFORMATION TO BREAKOUT THE EXACT AMOUNT FOR MATERIAL COSTS. PART XI LINE 9 OTHER CHANGES IN NET ASSETS CHANGE IN INTEREST IN ASSETS HELD BY AFFILIATE $ 83,131,936 CHANGE IN VALUE OF SWAP AGREEMENT $ (27,193,357) PENSION ADJUSTMENT $ 2,231,548 CUMMULATIVE EFFECT OF CHANGE IN ACCOUNTING PRINCIPLE $ 29,196,357 ---------------------- TOTAL OTHER CHANGES IN NET ASSETS $ 87,366,484 Dana-Farber Global Oncology LLC 450 BROOKLINE AV BP148 BOSTON MA 02215 851914853 Int. Oncology MA 0 0 DFCI Dana-Farber Inc 450 Brookline Avenue BP418 Boston MA 02215 043102433 INVEST MGMT MA 501(c)(3) 12A, TYPE I DFCI true Dana-Farber Trust Inc 450 Brookline Avenue BP418 Boston MA 02215 300195757 DFCI RE HOLDI MA 501(c)(3) 12a, type 1 DFCI true Dana-FarberPartners Cancer Care Inc 450 Brookline Avenue BP418 Boston MA 02215 043320640 ONC RESEARCH MA 501(c)(3) 12C, type 1 DFCI false RMSA Trust 450 Brookline Avenue BP418 Boston MA 02215 562656539 RETRMT TRUST MA 501(c)(9) DFCI true Friends of Dana-Farber Cancer Institute 450 Brookline Ave BP418 Boston MA 02215 371613621 Fundraising MA 501(c)(3) 12A, Type I DFCI true Dana-FarberChildren's Hosp Cancer Care 450 Brookline Avenue BP418 Boston MA 02215 043554536 Pediatric Onc MA 501(c)(3) 12A, type I NA Dana-Farber Cancer Care Network Inc 450 Brookline Avenue BP418 Boston MA 02215 465138314 ONCOLOGY CARE MA 501(c)(3) 509(A)(2) DFCI true false true true false false false false false false false false true true false true false false true true Dana-Farber Partners Cancer Care Inc O 35655 CASH Dana-Farber Partners Cancer Care Inc R 260354 cash Dana-Farber Partners Cancer Care Inc L 53226263 cash Dana-Farber Inc R 70104922 CASH Dana-Farber Inc s 272062587 CASH Friends of Dana-Farber Cancer Institute Inc c 667645 CASH Friends of Dana-Farber Cancer Institute Inc o 288556 Actual Exp Friends of Dana-Farber Cancer Institute Inc O 13113 cost Friends of Dana-Farber Cancer Institute Inc B 50000 CASH RMSA TRUST R 228514 Cash Dana-Farber Cancer Care Network Inc M 39698182 COST Dana-Farber Cancer Care Network Inc R 48628480 Cost